Introduction
The applicability of cancer therapies is not only determined by their efficiency in eliminating tumor cells. Their specificity is equally important. Tumor-cell specificity allows the dose of the anti-cancer agent to be increased, thereby enhancing efficacy. Recently, in vitro studies with the chicken anemia virus-derived protein apoptin (Leadd BV, Leiden, The Netherlands), demonstrated that this 121 amino acid protein has an intrinsic tumor-cell specificity. It induces programmed cell death in immortalized and transformed cells, but not in normal, diploid cells. In vitro studies have demonstrated that apoptin induces apoptosis in a large panel of human transformed and malignant cells. [1] [2] [3] Many of the malignant cells exhibit alterations in their expression of proto-oncogenes and tumor-suppressor genes, eg Bcl-2 4 or p53, 5 a phenomenon often associated with a poor response to chemotherapeutic agents. 4, [6] [7] [8] Remarkably, apoptin-induced apoptosis is not dependent on functional p53, 9 is not inhibited by Bcr-abl expression and is even stimulated by overexpression of the apoptosis inhibitor Bcl-2. 10 An attractive feature of apoptin is that it does not induce apoptosis in normal cells. 3 This is correlated with the subcellular localization of the protein. In normal cells, apoptin is in the cytoplasm whereas, in tumor cells, it is found in the nucleus. 3 This suggests that apoptin may be used as an agent that selectively eliminates malignant cells, provided that it can be delivered to target cells in vivo in sufficient amounts. One obvious strategy to reach this goal would be the application of the apoptin gene, rather than the protein itself.
At present the most efficient system to achieve this makes use of adenoviral vectors. These vectors have several advantages that make them particularly suitable for in vivo gene transfer. Recombinant adenoviral vectors (rAdVs) can be grown to high titers, have the capacity to transduce nonmitotic cells and do not integrate their genomes into host cell DNA. Moreover, adenovirus vectors have already been applied for clinical gene therapy trials.
In this paper, we describe the generation and characterization of an apoptin-expressing adenoviral vector. We demonstrate that apoptin maintains its specificity for tumor cells when introduced and expressed by an adenoviral vector. The intrinsic specificity and the inherent low toxicity make apoptin adenovirus vectors promising tools for the treatment of solid tumors.
Results
The effect of apoptin on helper cell lines Most adenovirus vectors are E1-deleted and are therefore replication-defective. It is necessary to propagate them in Ad5E1-transformed helper cell lines, such as 293, 11 911 12 and PER.C6. 13 This entails a potential problem, since apoptin induces apoptosis in transformed cells. One can, therefore, envisage that the helper cell line undergoes apoptosis due to the action of apoptin and that this may interfere with the formation of progeny vector particles. For this reason, the sensitivity of three helper cell lines to apoptin-induced apoptosis was determined. Cell lines 293, 911 and PER.C6 were transfected with pCMV-vp3, an expression plasmid encoding the apoptin gene.
1 At various time-points after transfection the cells were fixed, and the apoptin protein was visualized by indirect immunofluorescence. To identify apoptotic cells, the cells were also stained with DAPI, which stains normal nuclei strongly, but apoptotic nuclei weakly and/or irregularly.
14 Apoptin induces apoptosis with equal kinetics in the three cell lines. The percentage of apoptotic cells reaches up to 80% after 5 days. However, 48 h after transfection, about 25% of the cells expressing apoptin were apoptotic ( Figure 1 ). This is just above the background level of apoptosis observed after transfection of pCMV-desmin, which encodes desmin as a nonapoptosis-inducing control. 3 In the following days, the frequency of apoptosis increased, just as observed for other transformed cells tested in transient transfection assays.
2, 3 Since the lytic cycle of rAdVs is approximately 2 days, it is conceivable that an adenoviral vector expressing apoptin can be generated in all of these helper cell lines.
Generation of a recombinant adenoviral vector expressing apoptin Recombinant adenoviral vectors are generated by cotransfection of an adaptor plasmid containing the gene of interest with a plasmid containing a cloned copy of a partial adenovirus (Ad) type 5 genome into helper cells. Upon homologous recombination between sequences present in the adaptor and in the adenovirus plasmids, an Ad genome is generated in which the Ad E1-region is replaced by the gene of interest. This E1-deleted vector can replicate in the helper cells by virtue of the E1 proteins provided in trans by the helper cells. The gene encoding apoptin (vp3) was cloned in the Ad adaptor vector pMad5. 15 The resulting construct (pMad-vp3) is depicted in Figure 2a . Similarly, apoptin was inserted in the reverse orientation resulting in pMad-as, in order to generate a control virus that can be used in animal experiments to distinguish between the effects of the Ad vector and those of apoptin. Since the minus strand of the chicken anemia virus is noncoding, 16 no proteins will be expressed from the transgene of this control vector.
The recombinant adenoviral vector expressing apoptin (AdMLPvp3) and the control viral vector (AdMLPas) were generated by cotransfecting 911 helper cells with the linearized Ad adaptor constructs (pMad-vp3 and pMad-as) and pJM17, 17 containing an Ad5 genome lacking the E1 and E3 regions. The resulting plaques were isolated and after three rounds of plaque purification transferred to PER.C6 cells. These cells contain the E1 region regulated by a heterologous promoter which, combined with matched adaptor plasmids, eliminates the generation of replication-competent adenoviruses (RCA) by homologous recombination. 12 All batches of AdMLPvp3 were tested for apoptin expression by indirect immunofluorescence (Figure 2b ) and for the presence of RCA by a PCR assay, using primers directed to the E1 region giving rise to a band of 615 bp when RCA occurs (as described in Materials and methods). As expected, the AdMLPas control vector originating from pMad-as did not express apoptin. All the virus batches used passed an RCA test detecting 1 p.f.u. of an E1-containing adenovirus amidst 10 7 p.f.u. of an E1-deleted vector.
To investigate whether the expression of apoptin influences the virus yields, PER.C6 cells were infected with either AdMLPvp3 or AdCMVlacZ. The cells were harvested with 8-h intervals. The growth curves of AdMLPvp3 and AdCMVlacZ are similar, indicating that apoptin expression does not influence the vector yield (Figure 2c ). In all subsequent experiments, a harvest time of 48 h was used.
Characterization of AdMLPvp3
To determine whether apoptin also maintains its tumor cell specificity after adenovirus-mediated gene transfer, normal and transformed cells were infected with AdMLPvp3 and AdCMVlacZ. In view of the hepatotropic nature of human adenovirus type 5 after systemic delivery, 18, 19 we were particularly interested in the effect of apoptin on liver cells, and liver-derived tumor cells. Therefore, HepG2 and Hep3b human hepatoma cells (with and without functional p53, respectively) were infected with AdMLPvp3 and after 24 h expression of apoptin was determined (Figure 3a) . After 24 h, already 70-80% of the hepatoma cells expressing apoptin were undergoing cell death ( Figure 3b ). The background level of cell death is determined in parallel infections of the cells with AdCMV-lacZ. The ability of AdMLPvp3 to induce cell death in these transformed cells is equal to that of pCMVvp3 (not shown). So far, all normal cell types have been found to resist apoptin-induced apoptosis. The cell types that have been tested by transfection of an expression plasmid include normal keratinocytes, fibroblasts, endothelial cells, smooth muscle cells and T cells. 3 To study what the effect of the apoptin gene would be in normal cells when introduced by an adenoviral vector, primary rat hepatocytes were infected (Figure 3a) . After 2 days no difference was observed in the percentage of dead cells whether they expressed apoptin, or lacZ, or after mock infection ( Figure  3b ). These observations indicate that, in hepatocytes, the adenoviral vector does not influence the specificity of apoptin.
The data also show that apoptin maintains its characteristic localization after adenoviral transduction: nuclear in transformed cells and cytoplasmic in normal diploid cells (Figure 3a) . Moreover, transformed cells remain sensitive to apoptin-induced apoptosis, whereas normal cells are not.
To characterize the nature of AdMLPvp3-induced cell death further, we visualized the presence of DNA strand breaks with the aid of the enzyme terminal deoxynucleotidyl transferase and FITC-labeled dUTP (TUNEL assay). HepG2 cells were infected either with AdMLP-vp3 or with AdCMV-lacZ and after 20 h stained for the transgene to confirm similarity in transduction efficiencies (Figure 4 ).
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Figure 3 The effect of apoptin on primary and malignant hepatocytes. Primary rat hepatocytes and human hepatoma (HepG2 and Hep3b) cells were infected with AdMLPvp3 or AdCMVlacZ. For the hepatocytes, MOI of 5 was used, the hepatoma cells were infected with MOI 20 (panels a and b). (a) Forty-eight h after infection the cells were fixed and analyzed by indirect immunofluorescence. Apoptin was stained with mAb 85.1 (FitC) and the DNA was stained with DAPI (DAPI). (b) HepG2, Hep3b and primary rat hepatocyte cells were fixed 24 h after infection. The percentage of cells that stained abnormally with DAPI was used as a relative indicator of cell death. The percentages are given for cells expressing apoptin (black bars), ␤-galactosidase (grey bars) and non-infected cells. In each experiment at least 100 cells expressing apoptin or ␤-galactosidase were examined.
Figure 4 Apoptosis induction by AdMLPvp3. Parallel dishes of HepG2 were infected with AdMLPvp3 and AdCMVlacZ. After 20 h immunofluorescence was performed to detect the number of cells expressing apoptin and ␤-galactosidase assay was performed on the AdCMVlacZ infected cells to confirm comparable transduction efficiencies (± 10-15%). After 40 h a TUNEL assay was performed on parallel dishes, using FitC-labeled nucleotides.
After 40 h, parallel-infected dishes were subjected to the TUNEL assay. Even though approximately 15% of the HepG2 cells were expressing ␤-galactosidase, only occasionally a single cell exhibited DNA breaks that could be detected by the TUNEL assay. However, the frequency of TUNEL-positive cells 40 h after AdMLP-vp3 infection appeared to be in the same range as the frequency of apoptin-positive cells 20 h after infection.
The antitumor cell activity of AdMLP-vp3 is also demonstrated in vitro by the clearance of a dish of HepG2 cells 48 h after infection at MOI of 50. Giemsa staining visualizes the number of remaining cells attached to the dish, compared with the number of cells after infection with AdCMV-lacZ ( Figure 5 ). Inspite of a slight toxic effect of the adenoviral vector itself, as observed in the difference in cell density between the mock-and AdCMVlacZ-infected cells, these data confirm the potency of apoptin in killing tumor cells. Thus, in vitro, the HepG2 cells are killed via apoptosis within 48 h after infection with AdMLP-vp3.
Antitumor effect of AdMLP-vp3 on human hepatoma cells in vivo To investigate the antitumor effect of apoptin in vivo, 18 nude mice were injected with 1 × 10 7 HepG2 cells subcutaneously in both flanks. After 22 days, when the mean tumor dimensions were 50 mm 2 (n = 35), a single dose (equaling 8 × 10 9 p.f.u. in a total volume of 40 l) of either AdMLPvp3 (n = 12), AdMLPas (n = 12), AdCMVLacZ (n = 3) or saline (n = 8) was injected intratumorally. In the following days, the tumor sizes were determined up to the nearest 0.5 mm with microcalipers and all animals were killed at day 7.
To obtain an impression of the efficiency of virus distribution and tumor cell transduction after an intratumoral injection with an adenoviral vector, we performed a ␤-galactosidase staining on tissue sections obtained from AdCMV-lacZ-injected HepG2 tumors ( Figure 6 ). Since the tumors were isolated at the same time-point (7 days after injection), the original percentage of infected cells must have been even higher. Due to the lobular growth of HepG2 tumors, it is difficult to obtain an even distribution of the virus throughout the tumor, which is also demonstrated by the lacZ-staining patterns.
Tumors treated with AdMLPvp3 showed markedly reduced growth, whereas tumors injected with the control virus or saline did not (Figure 7a ). Growth rate was significantly lower in the AdMLPvp3-treated group than that in the buffer-treated (P Ͻ 0.05) and the AdMLPastreated groups (P Ͻ 0.02), as determined with a multiple comparisons test. The gene transfer into the tumors was confirmed by Southern blot analysis with the radioactively labeled apoptin gene as a probe (Figure 7c) .
Visually, the HepG2 tumors injected with a single dose of AdMLPvp3 differed from the control tumors: the treated tumors had a pale appearance and seemed to contain vesicle-like structures (Figure 7b ). Histological examination of AdMLPvp3-treated tumors revealed relatively hypovascularized tumor tissue, when compared with tumors treated with AdMLPas or saline. It seems possible that the reduction of vascularization is due to an indirect effect, ie caused by a reduced production of factors sti- mulating angiogenesis due to the apoptin-induced cell death.
Figure 5 Effect of AdMLPvp3 on viability of HepG2 cells. HepG2 cells were mock-infected (left dishes) or infected with AdMLPvp3 and AdCMVlacZ (MOI 50). After 48 h, four dishes were stained with Giemsa and two dishes were used for a ␤-galactosidase assay. Two parallel dishes of HepG2 cells were infected with AdMLPvp3 and AdCMVlacZ (MOI 50).
Toxicity of AdMLPvp3
To evaluate the possible toxic effects of AdMLPvp3, we injected 2 × 10 9 p.f.u. of virus (AdMLPvp3, AdCMVluc or saline) in healthy rats in three different manners: subcutaneously, intraperitoneally and intravenously.
Since body weight is generally a good indicator of health status within age-matched groups, we used this parameter as a criterion of well-being. It can be seen in Figure 8a that after an initial drop in weight after injection, all groups gained weight similar to control animals (range within 10%). After 1 week, all animals were killed.
To confirm efficient transduction of the cells of the liver parenchyma, DNA was isolated from the livers of all of three groups and used for Southern analysis (Figure 8b ). These data revealed efficient transduction after i.v. 
ng). Lanes 4-7 contain liver-derived DNA from rats intravenously injected with AdMLPvp3 (lanes 4 and 5) or AdCMVluc (lanes 6 and 7). Exposure time for lanes 4-7 was approximately 10 times longer than for the control fragments.
administration (approximately 0.25 genome equivalent per cell was detected 7 days after infection) and as expected, far less after i.p. and s.c. administration (less than 0.02 genome equivalents).
We previously observed an induction of a proliferative response of the liver parenchyma after systemic delivery of adenoviral vectors carrying different transgenes. We analyzed livers from animals intravenously injected with either saline, AdCMVluc or AdMLPvp3. BrdU labeling indices in liver parenchymal cells were similarly increased in both AdMLPvp3 and AdCMVluc treated rats compared with saline controls. This increase in BrdU incorporation was paralleled by a similar small increase in the frequency of apoptotic cells in both virus-treated groups (Table 1) .
For all administration routes, heart, lung, spleen, kidney, skin, testis and muscle samples were isolated for macroscopic evaluation and histological examination. No overt pathology was noted in these tissues, except for a slight increase in the mean spleen weight.
Also rats receiving a total of 8 × 10 9 p.f.u. AdMLPvp3 intravenously in four doses administered on 2 consecutive days, revealed no toxicity after 5 weeks (data not shown). The general parameters measured (including the The data are shown for the individual animals. Numbers represent the total number of BrdU-positive, apoptotic or mitotic cells in 100 randomly distributed areas, containing approximately 100 liver parenchymal cells each.
weights of total body, spleen and liver), were similar to those of the control groups at the end of the experiment. From these data we conclude that significant amounts of the AdMLPvp3 adenovirus vector can be administered without acute fatal toxicity.
Discussion
This report describes the generation of a recombinant adenoviral vector expressing apoptin and its effects on normal and on transformed cells. Our previous in vitro studies 2, 3 have shown that apoptin induces apoptosis in a range of human and rodent transformed and malignant cell lines, irrespective of p53, Bcl-2 or Bcr-abl status. We expected, therefore, that the generation and production of an adenovirus vector expressing the apoptin gene might be hampered by the transformed nature of the helper cell lines. However, apoptin-induced apoptosis in helper cells did not impede virus production. We previously showed that the 21-kDa Ad-E1B protein 20, 21 partially inhibits apoptin-induced apoptosis. Possibly, this protein somewhat delays the onset of apoptosis and therefore may facilitate propagation of adenovirus vectors that carry the apoptin gene.
We report here that, after adenovirus-mediated transfer of the apoptin gene, human hepatoma cells are susceptible to apoptin, whereas primary hepatocytes are not. Similar results with the vp3-containing vector were found for other combinations of cells, eg keratinocytes versus squamous cell carcinoma. In transformed cells, apoptin is located in the nucleus and may interact with nucleic acids through its basic character. Due to its high proline content, the presence of apoptin in the chromatin structure, may disturb the supercoiled organization resulting in DNA condensation and fragmentation. An alternative explanation might be that the basic and proline-rich character of the apoptin protein enables it to act as a transcriptional regulator resulting in the induction of genes mediating apoptosis. 22 It appears that infection of HepG2 cells with an adenoviral vector encoding apoptin leads to apoptosis faster than transfection with an expression vector. After DNA transfection, it takes approximately 3-4 days before 80% of the apoptin-expressing transformed cells become apoptotic. In contrast, after adenovirus-mediated transfer of the apoptin gene, this percentage is already reached after 24 h (Figure 3) . Apparently, the adenoviral infection somehow stimulates apoptin-induced apoptosis due to changes induced by the adenoviral infection, or alternatively, the effective intracellular level of apoptin is higher after viral infection than after transfection. Viral transduction does not, however, render normal cells sensitive to apoptin.
The animal studies presented in this paper demonstrate a low toxicity of apoptin in vivo, confirming and extending the results of the in vitro studies. Rats intravenously injected with either the apoptin-or luciferaseencoding virus vectors showed a comparable increase of proliferating hepatocytes (an indirect measurement for liver damage). Also previous experiments with other adenoviral vector studies revealed some increase in BrdU incorporation and the occurrence of apoptosis in these livers could be a response to the induction of the proliferative activity rather than a consequence of the transgene, especially since no difference is observed between the effects of the apoptin-and the control vector.
In a first test for antitumor activity, AdMLPvp3 was injected into tumors arising from human hepatoma cells transplanted into nude mice. We observed a significant antitumor effect by apoptin after a single intratumoral injection, despite the fact that this approach leads to transduction of only a part of the tumor. Given the finding that in vitro apoptin-containing HepG2 cells are killed within a few days it may not be surprising that we do not find a high apoptotic activity in AdMLPvp3-treated tumors when evaluated 7 days after treatment. However, in (pre)clinical studies nowadays, repeated doses of a vector, eg Ad-p53, are administered. [23] [24] [25] It is therefore reasonable to anticipate that with AdMLPvp3, too, repeated injections will be even more effective.
In addition, Soruri et al 26 have shown that apoptotic tumor cells can trigger dendritic cells to process and present responding T lymphocytes, which will result in acquired cytotoxic responsive inducing apoptosis in the nonaffected tumor cells. If this mechanism also holds true for apoptin-induced apoptosis, its antitumor effect will be more pronounced in immune-competent animals.
Southern blot analysis of the tumor material 1 week after injection with AdMLPvp3 showed that the viral DNA carrying the apoptin gene was still detectable. The presence of the apoptin gene after 1 week (Figure 7c ) may be due to infection of normal cells, eg stroma or endothelial cells.
The intrinsic tumor specificity of the apoptin gene makes it a promising new tool for cancer gene therapy. So far, attempts by others to obtain tumor-cell specificity rely on targeting the vector specifically to malignant cells, on tumor-specific expression of the transgene, or on local administration of the gene transfer vehicle. To date, the applicability of the available systems is limited by their relatively low efficiency, or by lack of specificity. [27] [28] [29] Promising results have been obtained with the HSVtk/gancyclovir combination in brain tumors, 30 but applicability of this system outside the central nervous system (brain) is hampered by toxic effects for certain normal tissues, eg the cells of the liver parenchyma. 31, 32 Another approach is based on the introduction of tumorsuppressor genes such as p53 or the retinoblastoma protein (RB) into tumor cells in which the endogenous counterparts are affected. 33, 34 The p53 approach combines two important features for cancer therapy: efficacy and specificity. For instance, studies with Ad-p53 show that re-expression of p53 in established tumors can induce apoptosis and tumor regression in vivo. 35 Both preclinical and clinical studies suggest a low toxicity for nontransformed cells when they are forced to express exogenous p53 at levels sufficient for tumor-cell killing. 23, 36, 37 However, the expression of wild-type p53 is most effective in cells lacking functional p53. Tumor cells expressing wild-type p53 are only marginally affected. 35 In vitro, at least, apoptin does not seem to discriminate between p53 − and p53
The tumor-cell specificity of apoptin makes it a valuable new addition to the list of approaches that can be explored for cancer gene therapy. Although our preliminary in vivo studies with AdMLPvp3 are promising, its potency and the more general applicability in other tumor cell types needs to be demonstrated.
Materials and methods
Cells and cell culture Ad5-E1 (nt 459-3510)-transformed human embryonic retina (PER.C6), 13 Ad5-E1 (nt 79-5789)-transformed human embryonic retina (911), 12 Ad5-transformed human embryonic kidney (293) 11 and human hepatoma (HepG2 38 and Hep3b 39 ) cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) in a 5% CO 2 atmosphere at 37°C. For immunofluorescence, cells were grown on glass microscope slides.
Primary rat hepatocytes were cultured in Williams E medium (Gibco Life Technologies, Grand Island, NY, USA) supplemented with insulin (2 mU/ml) and dexamethasone (1 mm). The cells were grown on collagen-coated culture slides (Micronic, Lelystad, The Netherlands).
Plasmids and transfection
Expression plasmid pCMV-vp3 contains CAV DNA sequences encoding apoptin (nt 427-868) under control of the cytomegalovirus promoter.
2 pCMV-desmin encodes desmin, a component of type II intermediate filaments and was used as a negative control for the induction of apoptosis. 40 Plasmid pMad5 15 contains the E1A enhancer linked to the major late promoter (MLP) to drive expression of the transgene. Downstream of the transgene, the region of the Ad5 genome comprising nt 3328-8914 is located and is used for recombination with homologous sequences in pJM17. 17 After a BamHI site was introduced into pMad5 to generate pMAD5/BamHI, the coding region of apoptin (nt 427-868) was inserted as a BamHI fragment, in both orientations. The resulting plasmids were named pMadvp3 and pMad-as. Plasmid DNA was purified by centrifugation in a CsCl gradient and column chromatography in Sephacryl S500 (Pharmacia, Uppsala, Sweden).
All transfections were performed by means of the calcium-phosphate precipitation procedure as described by Graham and Van der Eb. 41 Briefly, 2 h before transfection the medium of 80% confluent monolayers of PER.C6, 911 or 293 was replaced by fresh medium. DNA-calciumphosphate precipitates were incubated for 30 min at room temperature and subsequently added to the medium. The cells were washed twice with phosphatebuffered saline (PBS) after 24 h and fresh medium was added.
Immunofluorescence and DAPI staining Indirect immunofluorescence was performed as described previously. 42 To demonstrate the presence of apoptin and establish its cellular localization in transfected or infected cells, the cells were fixed with 80% acetone. The indirect immunofluorescence assay (IFA) was performed with a 100-fold dilution of the mouse monoclonal antibody (mAb) CVI-CAV-85.1 (85.1) for apoptin, 1 mAb 33 (Monosan, Uden, The Netherlands) for desmin and mAb lacZ (Boehringer Mannheim, The Netherlands) for ␤-galactosidase. Fluorescein-isothiocyanate-labeled goat anti-mouse antibody (Jackson Immunoresearch Laboratories, West Grove PA, USA) was used as second antibody. Nuclear DNA was stained with 1 g/ml 2,4-diamino-2-phenylindole (DAPI) in 2% 1, 4 diazabicyclo-[2,2,2]-octane in glycerol/0.1 m TrisHCl pH 8.0. 14 
Viruses and virus techniques
The recombinant adenoviral vector AdCMVlacZ carries the E. coli lacZ gene for ␤-galactosidase under control of the cytomegalovirus enhancer/promoter. AdCMVluc contains the firefly luciferase gene under control of the CMV enhancer/promoter.
A recombinant adenoviral vector expressing apoptin and a control vector were generated by cotransfecting near-confluent monolayers of 911 cells with equal amounts of pJM17 17 and pMad-vp3 or pMad-as (linearized by XmnI digestion). After 24 h the medium was removed and the cells were washed twice with PBS. F15 minimal essential medium (MEM) containing 0.85% agarose (Sigma, St Louis, MO, USA), 20 mm HEPES pH 7.4, 12.3 mm MgCl 2 , 0.0025% l-glutamine, and 2% horse serum (HS) (heat-inactivated at 56°C for 30 min), was added. After 8-10 days, plaques were extracted and subjected to three rounds of plaque purification. The recombinant adenoviruses (rAdvs) were subsequently transferred to PER.C6 cells by a limited dilution assay.
Large-scale production of adenovirus was performed according to Fallaux et al. 12 Briefly, near-confluent PER.C6 monolayers in 600-ml flasks were infected with approximately 5 plaque-forming units per cell, in 8 ml DMEM containing 2% HS. After 2 h at 37°C/5% CO 2 , 12 ml DMEM/10% FCS was added to each flask. After 48 h, the detaching cells were harvested and collected in PBS/2% HS. Virus was isolated from the producer cells by three cycles of freeze/thawing. The lysates were cleared by centrifugation at 2600 g for 5 min, and after dialysis against a sucrose-containing buffer, stored at −80°C.
Plaque assays were performed essentially as described by Graham and Prevec. 43 Briefly, adenovirus stocks were serially diluted in 1 ml DMEM/2% HS and added to near-confluent 911 cells in six-well plates. After 2 h of incubation at 37°C/5% CO 2 , the medium was replaced by agar-containing culture medium.
Quality control of rAdv batches
The expression of apoptin by the adenoviral vectors after infection of helper cells was tested by indirect immunofluorescence as described. The rAdV stocks were screened for the presence of replication-competent adenoviruses (RCA) by a polymerase chain reaction (PCR) assay. A 615-bp region was amplified with one oligonucleotide directed to the ITR of the adenoviral DNA (5ЈGGGTGGAGTTTGTGACGTG-3Ј) present in the Ad vector, and one to the region coding for the E1A protein (5ЈTCGTGAAGGGTAGGTGGTTC-3Ј), which is not present in the vector. The presence of the 615 bp product is indicative for the presence of RCA.
In brief, adenovirus supernatant (three times freezed/thawed) was degraded by digestion with proteinase K . After boiling, 5 l of the inactivated virus was added to 45 l of 50 mm KCl, 10 mm TrisHCl (pH 8.4), 0.1 mg/ml gelatine, 0.05% Tween20, 1.75 mm MgCl 2 , 0.1 mm of each deoxyribonucleotide, 20 pmol forward primer, 20 pmol reverse primer, 250 ng tRNA and 3 U of AmpliTaq DNA polymerase (Perkin-Elmer, Norwalk, CT, USA). PCR is performed for 30 cycles (94°C 1 min, 63°C 2 min, 72°C 3 min) in an automated DNA Thermal Cycler (Perkin-Elmer Cetus). DNA isolated from 911 cells infected with a pseudo-wild-type adenovirus (dl7001) served as a positive control. The assay has been optimized and detects 1 p.f.u. of an E1-containing adenovirus amidst 10 7 p.f.u. of E1-deleted vector (Van den Wollenberg and Hoeben, unpublished results).
TUNEL assay
Tdt-mediated dUTP nick end labeling (TUNEL) was performed with the use of the in situ cell death detection kit, fluorescein (Boehringer Mannheim). Forty hours after transfection cells were washed with PBS and fixed with 4% paraformaldehyde in PBS (pH 7.4), for 30 min at room temperature. After permeabilization (0.1% Triton X-100, 0.1% sodium citrate, 2 min at 4°C) cells were incubated with the TUNEL reaction mixture (containing fluorescein labeled nucleotide polymers and terminal deoxynucleotidyl transferase) for 1 h at 37°C. After washing with PBS, the cells were analyzed by fluorescence microscopy.
Giemsa staining and ␤-galactosidase assays For detection of the number of attached cells, cells were washed twice with PBS and fixed in methanol/acetic acid (3:1) for 15 min at room temperature. For 30 min, cells were incubated with Giemsa solution (3% Giemsa (Merck, Darmstad, Germany) in 1 mm Na 2 HPO 4 , pH 7.0) at room temperature. After staining, the cells were washed four times with deionized water and allowed to dry by air.
For detection of lacZ-encoded ␤-galactosidase activity, cells in tissue culture were fixed 48 h after infection in ice-cold 2% paraformaldehyde/0.2% glutaraldehyde solution, washed in ice-cold PBS (containing 2 mm MgCl 2 ), and incubated in 3 ml of reaction mix (1 mg/ml X-gal (Boehringer Mannheim), 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, 2 mm MgCl 2 in PBS) at 37°C for 4-16 h. 44 
Animals
Male Balb/c nu/nu mice, aged 7-8 weeks, and male Wag/Rij rats, weighing 180-210 g were obtained from Harlan (Zeist, The Netherlands). Animals were kept at standard laboratory conditions of alternating 12-h periods of light and darkness and a standard laboratory diet. The animal experiments were approved by the Leiden University Animal Welfare Committee.
Histology
Tissue sections were fixed in 4% buffered formalin. After paraffin-embedding, sectioning (approximately 4 micron) and mounting on slides, tissue sections were routinely stained with hematoxylin-eosin (HE).
In the toxicity experiment, rats were injected intraperitoneally with 50 mg/kg bromodeoxyuridine (BrdU; Sigma) in saline, 2 h before death. DNA-incorporated BrdU, as a measurement for cellular DNA replication, was detected immunohistochemically by a three-step immunoperoxidase staining with the anti-BrdU monoclonal antibody IU 4 . 45 Sections were counterstained with hematoxylin. Both HE and BrdU/H stained rat liver sections were analyzed using a Zeiss Axioplot microscope (Dena, Germany) and a 40 × objective. In HE-stained sections both apoptotic cells -characterized by dense, often fragmented, nuclei, eosinophilic cytoplasm and reduced contact with neighbour cells, and mitotic cells -defined by the absence of nuclear morphology, but the appearance of chromosomes in meta-, ana-or telophase were counted. In anti-BrdU sections we discriminated BrdUpositive liver parenchymal cells (relatively large round nuclei) from (all) other cell types in the liver. For each parameter, 100 randomly distributed areas were scored in each liver section (mostly containing 3-4 lobes) and each area contained approximately 150 nuclei.
For detection of AdCMVlacZ-encoded ␤-galactosidase, paraffin sections were stained with the polyclonal rabbit antibody 55978 (Cappel, Aurora, OH, USA). After deparaffinization, slides were incubated with the anti-␤-galactosidase antibody (55978, 1:2000) for 1 h at room temperature. As a second antibody biotinylated swine anti-rabbit (Dako, 1:300) was used, followed by streptavidin-conjugated peroxidase. Cells were rinsed with Trizma (Sigma) and positive cells were revealed by 15 min exposure to Dab solution in Trizma.
Southern blot analysis DNA was isolated from isopentane-fixed tissue and digested with BamHI. Southern 46 analyses were performed, by DNA fractionation on a 1% agarose gel and blotting on to Hybond + (Amersham, UK). The blots were hybridized with randomly primed 32 P-labeled DNA fragment encoding apoptin. In all assays BamHI digested pCMV-vp3 plasmid DNA was used as a control. The signals were quantified by phosphor imaging.
